Worcester, MA, March 22, 2005 - Dr. Robert Lanza, Vice President of Medical and Scientific Development at A.C.T. Holdings, Inc. (OTC Bulletin Board: ACTH) has been awarded the 2005 Rave Award for Medicine by Wired Magazine. Wired Magazine recognized Dr. Lanza for his commitment to finding cures through stem cell research and the Company's recent work in coaxing stem cells to develop into retinal cells, showing that researchers may look at the transcriptome, or pattern of mRNA expression, to help more quickly identify cells that will mature into specialized tissue. According to Dr. Lanza, the retinal cells that grow could lead to a cure for some forms of blindness.
Dr. Lanza credits his colleagues for their efforts, "This was really a team effort. Special credit should go to Dr. Irina Klimanskaya, who headed our effort to isolate retinal pigment epithelium from stem cells.”
In his interview with Wired Magazine, Dr. Lanza commented, "There are 3,000 Americans dying every day from diseases I believe could be treated using stem cell technology.” He also cited advice from some of his mentors, including Jonas Salk, B.F. Skinner, and Christiaan Barnard. That advice was to "Make a difference.”
William Caldwell, Chief Executive Officer of ACT Holdings, Inc. said, "It is gratifying to see the technology community recognizing the importance of regenerative medicine and the scientists working in the field.”
Michael D. West, Chairman, President, and Chief Scientific Officer of Advanced Cell Technology, Inc. commented, "I am very happy for Dr. Lanza's continued recognition in the field of stem cell research. Dr. Lanza has long been and will continue to be an important leader and contributor to our scientific team at Advanced Cell Technology.”
A.C.T. Holdings, Inc., a Nevada corporation, is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company is currently headquartered in Worchester, Massachusetts. The company intends to establish a research facility in California, where voters last November passed Proposition 71. Often referred to as the "Stem Cell Initiative”, Proposition 71 provides $3.0 billion over the next ten years for stem cell research.
This press release contains forward looking statements that involve risks and uncertainties. Actual results, events and performance could vary materially from those contemplated by these forward-looking statements. These statements involve known and unknown risks and uncertainties that may cause the company's actual results in future periods to differ materially from results expressed or implied by forward-looking statements. You should not place undue reliance on forward-looking statements because they involve these risks and uncertainties. You should independently investigate and fully understand all risks before making investment decisions.
A.C.T. Holdings, Inc.